pulsed methylprednisolone ( pmp ) has been shown to produce clinical improvement and reduction in the esr and acute phase protein concentrations in patients with active rheumatoid arthritis and has been advocated for use either as an alternative to slow-acting antirheumatoid drugs ( saards ) or in conjunction with saards to accelerate the response to treatment .
C0025815
methylprednisolone
C0003873
rheumatoid arthritis